Theophylline is under clinical development by Cyrano Therapeutics and currently in Phase II for Dysgeusia (Taste Disorders). According to GlobalData, Phase II drugs for Dysgeusia (Taste Disorders) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Theophylline LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Theophylline overview
Theophylline is under development for the treatment of hyposmia and hypogeusia. The drug candidate is administered through intranasal route. It acts by targeting phosphodiesterase.
Cyrano Therapeutics overview
Cyrano Therapeutics (Cyrano Therapeutics) is a clinical stage regenerative medicine company. The company develops therapy for people struggling with the loss of smell and flavor. It creates a special, exclusive intranasal medication to help patients with chronic loss of taste and smell regain function. The company offers Cyrano product (CYR-001) for treatment of Otolaryngologist (Ear, Nose, and Throat specialist) and credible clinical investigators. It operates in North America, and Europe. Cyrano Therapeutics is headquartered in Delray Beach, Florida, the US.
For a complete picture of Theophylline’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
